Bass challenges Acorda patents again

Kyle Bass' Coalition for Affordable Drugs filed three new inter partes review (IPR) petitions challenging patents covering Ampyra dalfampridine from Acorda Therapeutics Inc. (NASDAQ:ACOR) on grounds of obviousness.

Two of the petitions challenge U.S. Patents Nos. 8,007,826 and 8,663,685. Last week, the Patent Trial and Appeal Board denied separate IPR petitions from Bass against those two patents (see BioCentury Extra, Aug. 27). ...